Currently, compound 86, namely E-7016 (PARP-1 IC50 = 0.04 μM), is under evaluation in combination with temozolomide in patients with advanced solid tumors or with wild-type BRAF stage IV or unresectable stage III melanoma [71]. The gene discussed is PARP1; the disease is melanoma.